The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Altuntas, C. Z.
Right arrow Articles by Tuohy, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altuntas, C. Z.
Right arrow Articles by Tuohy, V. K.
The Journal of Immunology, 2006, 177: 1988-1996.
Copyright © 2006 by The American Association of Immunologists

Autoimmune Targeted Disruption of the Pituitary-Ovarian Axis Causes Premature Ovarian Failure1

Cengiz Z. Altuntas*,{dagger}, Justin M. Johnson* and Vincent K. Tuohy2,*,{dagger}

* Department of Immunology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195; and {dagger} Department of Biology, Cleveland State University, Cleveland, OH 44115


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Premature ovarian failure (POF) is characterized by amenorrhea and high serum levels of follicle-stimulating hormone (FSH). POF causes female infertility and represents a substantial women’s health risk affecting 1% of women by age 40. Although ovarian autoimmunity has been associated with POF, the identity of ovarian Ags recognized is unknown. In this study, we show that autoimmune-targeted disruption of the pituitary-ovarian axis leads to POF. Immunization of SWXJ female mice with the p215–234 peptide derived from mouse inhibin-{alpha} activates CD4+ T cells and induces experimental autoimmune oophoritis with a unique biphasic phenotype characterized by an early stage of enhanced fertility followed by a delayed stage of POF. Affected mice show high serum levels of inhibin-{alpha}-neutralizing Abs that prevent inhibin-mediated down-regulation of activin-induced pituitary FSH release. The loss of activin/FSH down-regulation leads to prolonged metestrus-diestrus, superovulation, increased numbers of mature follicles, increased offspring, accelerated depletion of primordial follicles, and ultimately premature infertility. Thus, inhibin-{alpha}-targeted experimental autoimmune oophoritis is initiated by CD4+ Th1 T cells that stimulate B cells to produce inhibin-{alpha}-neutralizing Abs directly capable of mediating POF and transferring disease into naive recipients. Our inhibin-{alpha} autoimmune model of POF shows how premature infertility may develop in the context of elevated FSH levels thereby closely mimicking the hallmark features of human POF.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Premature ovarian failure (POF),3 sometimes referred to as premature ovarian insufficiency, is characterized by disrupted menstrual cycles and high serum levels of follicle-stimulating hormone (FSH) and causes female infertility affecting an estimated 1% of American women in their childbearing years (1, 2). Many cases of POF have been linked to chromosomal, genetic, enzymatic, infectious, and iatrogenic causes. However, the underlying etiopathogenic mechanism causing most POF cases remains unresolved.

Autoimmunity has been implicated in POF with many cases associated with established autoimmune conditions, most notably Addison’s disease, a primary autoimmune adrenal insufficiency (3). POF patients also have increased circulating CD19+CD5+ B cells often associated with autoimmunity (4, 5) and have serum autoantibodies that immunostain ovarian tissues or bind to ovarian homogenates in ELISA (6). However, the identity of ovarian Ags recognized by POF autoantibodies is currently unknown (7).

Experimental autoimmune oophoritis (EAO) has been extensively used to study POF. EAO may be induced in rats and BALB/c mice by immunization with ovarian homogenate in CFA (8, 9). Serum ovarian Abs appear after 28 days and may passively transfer decreased fertility measured by decreased litter size into naive recipients (8, 10). EAO may also be induced in rabbits (11) or mice (12) by immunization with the zona pellucida-3 (ZP3) sperm receptor (13). Activated ZP3-specific CD4+ T cells are sufficient for transferring EAO in naive recipient B6AF1 mice (12, 14). EAO occurs spontaneously in neonatally thymectomized BALB/c mice that also develop multiple autoimmune disorders of the thyroid, gut, and parotid gland (15, 16). The EAO occurring in neonatally thymectomized mice appears to be due to regulatory T cell deficiencies (15, 16) because transfer of normal CD4+ or CD8+ T cells into athymic BALB/c nude mice also causes EAO (17).

Despite the usefulness of these currently available EAO models for studying POF, none has provided clinically useful insights into how autoimmune events may lead to elevated FSH and POF. However, recent studies indicating the association of deficient FSH down-regulation and POF with defined variants of the inhibin-{alpha} protein (18) or the inhibin-{alpha} promoter (19) suggested to us that POF may similarly occur following inhibin-{alpha}-targeted autoimmunity.

Ovarian function is regulated primarily by a pituitary-ovarian axis comprised of activins and inhibins that are produced primarily in ovarian granulosa cells (20) and serve, respectively, as positive and negative regulators of the pituitary gonadotrophins, FSH, and luteinizing hormone (LH; Refs. 21, 22, 23). Activins are homo- or heterodimers of betaA and betaB chains shared by inhibins that contain a unique {alpha}-chain not found in the activins. Inhibins antagonize activin-induced FSH production, oocyte maturation, ovulation, and fertility primarily by binding antagonistically to activin receptors (24, 25, 26). We hypothesized that an autoimmune-targeted disruption of the pituitary-ovarian regulatory axis may lead to ovarian dysregulation and POF.

In this study, we describe a novel form of EAO induced by a CD4+ targeted attack directed against inhibin-{alpha}, the negative regulator of FSH release. Immunization of SWXJ female mice with the p215–234 sequence of inhibin-{alpha} activates CD4+ T cells and induces a biphasic form of EAO involving an early phase of enhanced fertility and a delayed phase of POF. We found that In{alpha} 215–234-induced EAO is initiated by CD4+ T cells but mediated by B cells and Ab neutralization of inhibin-{alpha} that prevents regulation of activin-induced FSH release leading to elevated FSH, superovulation, increased production of mature follicles, increased numbers of viable offspring, and ultimately, an accelerated depletion of primordial follicles that leaves affected mice with ovarian failure. Our EAO model of POF shows mechanistically how autoimmune-targeted disruption of ovarian regulation may lead to premature infertility in the presence of elevated FSH levels, the hallmark features of human POF.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice and immunization

All mice were purchased from The Jackson Laboratory. SWXJ (H-2q,s) mice were generated at The Jackson Laboratory by mating SJL/J (H-2s) males with SWR/J (H-2q) females. At 6–8 wk of age, mice were injected s.c. in the abdominal flank with 200 µg of either peptide or the irrelevant OVA control Ag (Sigma-Aldrich), in 200 µl of an emulsion of equal volumes of water and CFA containing 400 µg of Mycobacteria tuberculosis H37RA (Difco). Mice were euthanized by asphyxiation with CO2 followed by cervical dislocation. All protocols were preapproved by the institutional animal care and use committee of the Cleveland Clinic Foundation in compliance with the Public Health Service policy on humane care and use of laboratory animals.

Peptides

Peptides were derived from the known sequence of mouse inhibin-{alpha} (27, 28) and were selected based on having the -KXXS- tetrapeptide-binding motif for IAs and IAq MHC class II molecules expressed in SWXJ mice (29). Peptides were synthesized by the Molecular Biotechnology Core Facility of the Lerner Research Institute using standard solid phase methodology and F-moc side chain-protected amino acids. Peptides were purified >97% by reverse-phase HPLC, and amino acid composition was confirmed by mass spectrometry.

Cell culture and proliferation assay

To determine peptide immunogenicity, lymph node cells (LNC) removed 10 days after immunization (10-day-primed LNC) were cultured in 96-well flat-bottom microtiter Falcon plates (BD Labware) at 3 x 105 cells/well in DMEM (Mediatech CellGro) supplemented with 10% FBS (HyClone), 5% HEPES buffer, 2% L-glutamine, and 1% penicillin/streptomycin (Invitrogen Life Technologies). Peptides were added in serial 10-fold dilutions to triplicate wells with positive control wells containing 2 µg/ml anti-mouse CD3 (BD Biosciences) and negative control wells containing no Ag. Cells were cultured at a final volume of 200 µl/well. In some experiments, primed CD4+ and CD8+ T cells were purified from 10-day-primed LNC by negative selection using anti-CD4- and anti-CD8-coated magnetic beads and double passage through a MACS LS column using a MidiMACS cell separator (Miltenyi Biotec). The purified cells were activated with various doses of peptide in cultures containing 3 x 105 T cells/microtiter well and 5 x 105 gamma-irradiated (2500 rad) syngeneic splenocyte feeders. To measure recall responses to immunogens, spleens were removed 8–9 wk after immunization, mononuclear cells were enriched by centrifugation on density gradient medium Lympholyte-M (Accurate Chemical) and cultured as described above. All cell cultures were incubated at 37°C in humidified air containing 5% CO2. After 96 h, wells were pulsed with [methyl-3H]thymidine (1.0 µCi/well, specific activity 6.7 Ci/mM; New England Nuclear) and harvested 16 h later by aspiration onto glass fiber filters. Levels of incorporated radioactivity were determined by scintillation spectrometry. Results are expressed as mean cpm of experimental cultures with Ag divided by mean cpm of cultures without Ag (stimulation index). In all proliferation assays, mean cpm of cultures without Ag ranged between 500 and 2000 cpm.

Cytokine ELISAs

Cytokine concentrations were determined by ELISA measurement of 48 h supernatants of 10-day-primed LNC cultured in supplemented DMEM at 5 x 106 cells/well in 24-well flat-bottom Falcon plates (BD Biosciences) in the presence of 20 µg/ml Ag in a final volume of 2.0 ml/well. Purified capture/detection Ab pairs and recombinant cytokines were obtained commercially (BD Biosciences) and included anti-mouse IFN-{gamma} (R4-6A2 and biotin XMG1.2), anti-mouse IL-2 (JES6-1A12 and biotin JES6-5H4), anti-mouse IL-5 (TRFK5 and biotin TRFK4), and anti-mouse IL-10 (JES5-2A5 and biotin SXC-1). Absorbance was measured at 405 nm using a model 550 ELISA microplate reader (Bio-Rad). Standard values were plotted as absorbance vs cytokine concentration, and sample cytokine concentrations were determined as values within the linear part of the standard curve established using known concentrations of each cytokine.

Hormone ELISAs

At 4 and 12 wk after immunization, serum inhibin-A and activin-A were measured by direct ELISA as previously described (30, 31, 32, 33). To enhance specificity and sensitivity, all serum samples and standards were pretreated with SDS, heated to 100°C, and exposed to H2O2. Inhibin-A and activin-A were measured using a common solid-phase capture Ab specific for the betaA chain and anti-inhibin-{alpha} or anti-betaA alkaline phosphatase-conjugated detection Ab that, respectively, distinguished inhibin-A from activin-A (Serotec). Following addition of substrate, alkaline phosphatase activity was determined by detecting absorbance at 620 nm using a model 550 ELISA microplate reader (Bio-Rad). Serum FSH was measured by radioimmunoassay at the National Hormone and Peptide Program (Harbor-UCLA Medical Center, Torrance, CA) as previously described (34).

Immunocytochemistry

Mouse ovaries were fixed in 10% phosphate-buffered Formalin (Fisher Scientific) and embedded in paraffin. For T cell immunostaining, 5-µm sections were sequentially unmasked in 1 mM EDTA (pH 8.0), blocked with 5% normal goat serum (Vector Laboratories), incubated with a 1/10 dilution of rat anti-mouse CD3 (clone NCL-CD3-12; Novocastra Laboratories), incubated with a 1/50 dilution of mouse-adsorbed biotinylated goat anti-rat IgG (BD Biosciences), treated with 1.5% H2O2 in methanol, and developed by sequential treatment with a streptavidin-HRP complex (ABC kit; Vector Laboratories), diaminobenzidine, and H2O2 substrate (BioGenex). Slides were counterstained with H&E (Richard-Allan Scientific), dehydrated in an ascending gradient of ethanol followed by xylene, and mounted in Cytoseal 60 (Stephens Scientific) for examination by light microscopy.

Fertility assessments

To determine fertility phenotypes, test and control female mice were mated serially with the same SWXJ males over six mating periods. All mice were age matched.

Quantification of ovarian follicles

Ovaries were collected at 4 wk, fixed in 10% phosphate-buffered Formalin (Fisher Scientific), and embedded in paraffin. Follicles were counted under light microscopy in every 10th 5-µm H&E-stained section. Small, medium, and large antral follicles were distinguished based on their widest cross-sectional diameter and their morphology (35). Healthy follicles were considered as those with 200–500 cells in the largest cross-section were considered (36). Atretic follicles were distinguished according to the percentage of pyknotic nuclei among the granulosa cells, the presence of neutrophils in the follicles, and the presence of cavities in follicles with fewer than 200 cells in the largest cross-section. Total follicles for each mouse was determined as the sum counted in both ovaries.

Estrous cycle staging

At 4 wk after immunization, vaginal smears were collected in 20 µl of 0.9% NaCl and transferred to a glass slide daily at the same time each morning. After air drying, samples were fixed in methanol, stained with methylene blue in 9.5% ethanol, washed and coverslipped. The four stages of the estrous cycle were determined as previously described (37, 38) with proestrus showing 100% intact live epithelial cells, estrus showing 100% cornified epithelial cells, metestrus showing ~50% cornified epithelial cells and ~50% leukocytes, and diestrus showing 80–100% leukocytes.

Ab isotyping

Isotype-specific Ab titers to In{alpha} 215–234 were determined in serum samples according to manufacturer’s instructions using the mouse MonoAB ID/SP ELISA kit (Zymed Laboratories).

Passive transfer of EAO

Four weeks after immunization of female SWXJ mice with 200 µg of either In{alpha} 215–234 or OVA as an irrelevant control Ag (Sigma-Aldrich), splenocytes were activated in vitro with 20 µg/ml of each immunogen at 5 x 106 cells/ml in 24-well flat-bottom Falcon plates (BD Biosciences) in a total volume of 2.0 ml/well in DMEM supplemented as described above. After 4 days, 2 x 107-activated cells were injected i.v. into naive female recipients. In some experiments, CD4+ T cells were positively purified from activated cultures by incubation of cells with anti-CD4-coated magnetic beads and passage through a MACS LS column using a MidiMACS cell separator (Miltenyi Biotec). The positively selected CD4+ T cells (purified >95%) were also injected i.v. into naive female recipients at 2 x 107 cells/mouse. Similarly, 4 wk after immunization B cells were purified (>90%) directly from spleens of primed mice without any prior in vitro activation by magnetic bead separation using anti-B220-coated microbeads (Miltenyi Biotec). The purified B cells were injected i.p. at 2 x 107 cells/naive recipient. Finally, 4 wk after immunization, sera from In{alpha} 215–234 and OVA-immunized mice were collected by intracardiac bleeding. Naive recipients received four 300-µl tail vein injections of primed sera administered every other day. Four weeks after transfer of cells or sera, mice were mated with the same male mice for determining the impact of treatment on fertility and litter size.

Neutralization experiments using LbetaT2-immortalized cells

LbetaT2 pituitary cells were provided by Dr. P. L. Mellon (University of California, San Diego, CA) and were grown as previously described (39) in 25-ml T flasks (Corning) to ~50% confluence in DMEM containing 4500 mg/L glucose (Mediatech CellGro), 110 mg/L pyruvate, 548 mg/L L-glutamine (Invitrogen Life Technologies), 10% FBS (HyClone), and 1% penicillin/streptomycin (Invitrogen Life Technologies). Cells were maintained at 37°C in 95% air and 5% CO2. Before testing, LbetaT2 cells were grown in DMEM growth medium without serum. Cell concentrations were adjusted to 2.5–3.5 x 105 cells/microtiter well in a volume of 180 µl. To this volume, 20 µl of varying dilutions of sera were added to a final volume of 200 µl. The diluted sera also contained 25 ng/ml recombinant activin-A (R&D Systems) for inducing FSH production and varying concentrations of recombinant inhibin-A (DSL) for determining whether sera contained neutralizing Ab capable of preventing inhibin-A from inhibiting activin-A-induced FSH production. After 2 days, supernatant FSH levels were measured by competitive ELISA as described previously. A total of 20 µl of PBS and 20 µl of charcoal/dextran-treated FBS (HyClone) were used as additional controls. LbetaT2 cells showed >90% viability whether cultured in growth medium alone or in growth medium supplemented with 25 ng/ml activin and 25 ng/ml inhibin.

Statistical analysis

The unpaired Student t test was used to analyze differences in fertility, estrous cycle, follicle numbers, and hormone levels between inhibin-{alpha} and control-immunized mice.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Induction of EAO in SWXJ mice immunized with In{alpha} 215–234

To identify immunogenic inhibin-{alpha} peptides, we applied the -KXXS- tetrapeptide sequence motif associated with IAq- and IAs-restricted CD4+ immunogenicity. Peptides containing a tetrapeptide sequence with a lysine or conservatively substituted arginine residue separated by two irrelevant amino acids from a serine residue have been shown to be immunogenic and capable of inducing several CD4+ T cell-mediated autoimmune diseases in SWXJ (H-2q,s), SWR/J (H-2q), and SJL/J (H-2s) mice (29).

We synthesized several -KXXS- containing 20-mer peptides derived from the known sequence of mouse inhibin-{alpha} (27, 28) and immunized female SWXJ mice with 200 µg of each peptide in CFA. One of the selected peptides, In{alpha} 215–234 elicited a substantial recall proliferative response from 10 day-primed LNC, whereas the remaining peptides were relatively nonimmunogenic (Fig. 1A). ELISA analysis of 48 h culture supernatants showed that recall responses to In{alpha} 215–234 involved a proinflammatory Th1-like phenotype with high level Ag-inducible production of IFN-{gamma} and IL-2 and minimal production of IL-5 and IL-10 (Fig. 1B). When CD4+ and CD8+ T cells from In{alpha} 215–234-primed mice were enriched >90% by magnetic bead separation and stimulated with peptide on a gamma-irradiated (2000 rad) splenocyte monolayer, recall responses were confined to the CD4+ subpopulation (Fig. 1C). Responsiveness to In{alpha} 215–234 was elicited by 10 day-primed LNC from peptide-immunized SWXJ and SJL/J mice but not from parental SWR/J mice indicating that the response to In{alpha} 215–234 was restricted by IAs (Fig. 1D).


Figure 1
View larger version (65K):
[in this window]
[in a new window]
  		FIGURE 1. In{alpha} 215–234 induces EAO in SWXJ mice. Female SWXJ mice were immunized with selected mouse inhibin-{alpha} peptides expressing the -KXXS- tetrapeptide motif. Ten days after immunization, LNC were tested for recall proliferative responses to each peptide immunogen. A, Peptide In{alpha} 215–234 elicited marked dose-response immunoreactivity. B, ELISA analysis of 48-h culture supernatants showed that recall responses to In{alpha} 215–234 involved the proinflammatory Th1-like phenotype with elevated production of IFN-{gamma} and IL-2 and minimal production of IL-5 and IL-10. C, Responses to In{alpha} 215–234 were confined to CD4+ T cells enriched >90% by magnetic bead separation. D, Responses were restricted by IAs because 10 day-primed LNC from parental SJL/J but not SWR/J mice responded to the peptide. E, Ovarian tissue sections immunostained with CD3 Ab show perifollicular infiltration of CD3+ T cells 8 wk (arrow, left panel) and 12 wk (arrow, middle panel) after immunization with In{alpha} 215–234. Infiltration of CD3+ T cells was never observed in any control mice immunized with CFA alone (right panel). All figures are representative of seven to eight mice examined in each group at each time point. Solid bar, 50 µm. All error bars indicate ± SD.

 
To determine whether the immunogenic In{alpha} 215–234 peptide was capable of inducing EAO, we immunized female SWXJ mice with 200 µg of the peptide in CFA and assessed disease induction by immunocytochemical analysis of ovarian tissue 8 and 12 wk after immunization. We consistently observed infiltration of CD3+ T cells in the perifollicular granulosa cell region of ovarian follicles 8 wk (Fig. 1E, left panel) and 12 wk (Fig. 1E, middle panel) after immunization with In{alpha} 215–234. In contrast, we never observed ovarian infiltrates of CD3+ T cells in mice immunized with CFA alone (Fig. 1E, right panel). The ovarian T cell infiltrations in In{alpha} 215–234-immunized mice are consistent with an induced autoimmune oophoritis.

EAO mice have longer estrous cycles

Vaginal smears show changes in the structure of the vaginal epithelium and follow a regular and predictable sequence across the course of each estrous cycle. To determine the effect of In{alpha} 215–234 immunization on the estrous cycle, vaginal smears were obtained daily and examined for changes in their cellular content over several estrous cycles. The mean duration of each estrous cycle as well as the length of time spent in each stage were determined for peptide (Fig. 2A) and CFA-primed mice (Fig. 2B). Mice immunized with In{alpha} 215–234 had significantly longer estrous cycles (p = 0.017) than mice immunized with CFA alone (Fig. 2C). The mean length of the estrous cycle in In{alpha} 215–234-immunized mice was 8.5 ± 0.441 days whereas the mean duration of each estrous cycle in control mice immunized with CFA alone was 7.275 ± 0.248 days. The lengthening of the estrous cycle in In{alpha} 215–234-immunized mice involved a significant shortening (p = 0.043) of the duration of proestrus-estrus (mean 2.609 ± 0.17 days) compared with mice immunized with CFA alone (mean 3.125 ± 0.179 days, Fig. 2D) and a significant (p = 0.002) lengthening of metestrus-diestrus (mean 5.9 ± 0.416 days) compared with controls (mean 4.15 ± 0.17 days). Thus, EAO lengthens the estrous cycle by prolonging metestrus-diestrus associated with follicle development and shortening proestrus-estrus associated with ovulation and fertilization.


Figure 2
View larger version (54K):
[in this window]
[in a new window]
  		FIGURE 2. Immunization with In{alpha} 215–234 prolongs the estrous cycle and increases FSH and follicle production. Vaginal smears were examined over five estrous cycles starting 4 wk after immunization of SWXJ mice with (A) In{alpha} 215–234 or (B) CFA alone. Each vertical bar represents five estrous cycles of a single mouse with each completed estrous cycle represented by adjoining pairs of solid (proestrus-estrus) and diagonally striped (metestrus-diestrus) segments. Horizontal dotted lines are for reference only. C, Immunization with In{alpha} 215–234 increases the duration of the estrous cycle (n = 40; p = 0.17) by (D) shortening proestrus-estrus (p = 0.04) and lengthening metestrus-diestrus (p = 0.002). E, Four weeks after immunization, total follicle numbers as well as small, medium, large, and atretic follicles were significantly increased in In{alpha} 215–234-immunized mice (p < 1 x 10–6 in all group comparisons). F, During estrus, In{alpha} 215–234-immunized mice had significantly increased activin (left panel, p = 0.01) and inhibin (right panel, p = 0.03) serum levels. Serum inhibin was also significantly elevated during metestrus (right panel, p = 0.03). G, Serum FSH levels were also significantly elevated during estrus at both the early stage (7–9 wk; p = 0.01) and late stage (43–45 wk; p = 0.05) of EAO induced by immunization with In{alpha} 215–234. All error bars indicate ± SD.

 
EAO mice have increased numbers of ovarian follicles

We next determined the impact of In{alpha} 215–234 immunization on the number of ovarian follicles. Four weeks after immunization with either In{alpha} 215–234 or CFA alone, ovarian tissue sections were examined for the presence of follicles. Follicles were counted under light microscopy in every 10th 5-µm H&E-stained section to avoid counting the same follicle twice. We found that the differences in the mean total number of follicles, as well as in the mean numbers of small, medium, large, and atretic follicles were highly significant (p < 1 x 10–6 in all cases) between mice immunized with In{alpha} 215–234 and mice immunized with CFA alone (Fig. 2E). The mean numbers of total (433.52 ± 12.57), small (305.91 ± 12.1), medium (86.16 ± 6.4), large (41.41 ± 2.1), and atretic (32.41 ± 2.4) follicles in In{alpha} 215–234-immunized mice all were higher than the mean numbers of total (214.41 ± 14.13), small (158.25 ± 11.9), medium (36.25 ± 2.6), large (19.91 ± 0.9), and atretic (10.5 ± 1.24) follicles in CFA-immunized control mice. It is worth noting that there were no apparent morphologic differences in the appearance of follicles within each group. Thus, the increase in follicle numbers is consistent with the view that immunization with In{alpha} 215–234 resulted in superovulation.

EAO mice have elevated serum levels of FSH, activin, and inhibin

We next examined whether EAO alters the level of hormones involved in pituitary-gonadal regulation. At different times after immunization, sera were collected from EAO and control-immunized mice at estrus and metestrus. By 4 wk after immunization, serum concentrations of activin-A were significantly higher (p = 0.01) in In{alpha} 215–234-immunized mice compared with controls during the estrus stage but not during metestrus (Fig. 2F, left panel). In contrast, serum levels of inhibin-{alpha} at 4 wk (Fig. 2E, right panel) were significantly elevated in In{alpha} 215–234-immunized mice compared with controls during both estrus (p = 0.03) and metestrus (p = 0.03). Serum FSH levels (Fig. 2G) were also significantly elevated during estrus at both the early stage (7–9 wk; p = 0.01) and late stage (43–45 wk; p = 0.05) of EAO induced by immunization with In{alpha} 215–234. Thus, despite the fact that serum inhibin concentrations were elevated during the entire course of the estrous cycle, their increased levels were unable to prevent the activin-induced FSH surge that was evident during estrus.

EAO is biphasic with early increased fertility and delayed ovarian failure

We next examined the reproductive phenotype of female SWXJ mice immunized with In{alpha} 215–234. Test and age-matched control mice were mated to the same males for the same period of time and the number and weight of offspring were determined. We found that mice mated 7–9 wk after immunization with In{alpha}-215–234 showed significantly increased fertility as determined by differences in mean litter size (p = 0.003) and mean litter weights (p = 0.003) with no significant difference in mean birth weights (p = 0.10; Table I, upper). In contrast, when mated at 43–45 wk after immunization, the same In{alpha} 215–234-immunized mice showed dramatically opposite results with significant decreased fertility determined by differences in mean litter size (p = 0.0002) and mean litter weights (p = 0.0004). Again, there was no significant difference in mean birth weights between both treatment groups (p = 0.76; Table I, lower).


View this table:
[in this window]
[in a new window]
  		Table I. In{alpha} 215-234-induced biphasic EAO with early increased fertility and delayed POF

 
When sequential litter sizes are plotted with time after immunization, it is readily apparent that the early enhanced fertility as measured by mean litter size is ephemeral in In{alpha} 215–234-immunized mice and declines gradually with time (Fig. 3A). The early enhanced fertility in In{alpha} 215–234-immunized mice was accompanied by hypertrophic ovaries with increased numbers of follicles and an overall morphology consistent with superovulation (Fig. 3B, upper left). In sharp contrast, ovaries from mice taken 43–45 wk after immunization with In{alpha} 215–234 consistently appeared atrophic with few follicles (Fig. 3B, lower left), a morphology consistent with POF particularly because CFA-immunized control mice showed neither a substantial decline in litter size or observable differences in ovarian morphology over the course of the study (Fig. 3B, upper and lower right).


Figure 3
View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 3. Immunization with In{alpha} 215–234 induces biphasic EAO. A, Serial mating of mice immunized with In{alpha} 215–234 showed an initial enhanced fertility as measured by mean litter size. However, mean litter size in mice immunized with In{alpha} 215–234 gradually declined over time, and by 43–45 wk was significantly below the mean litter size of age-matched control mice immunized with CFA alone (p = 0.0002). Details of fertility data derived from mice mated 7–9 wk and 43–45 wk after immunization are provided in Table I. Error bars show ± SD. B, Representative H&E-stained ovarian sections show extremely large superovulating ovaries 7–9 wk after immunization with In{alpha} 215–234 (upper left). By 43–45 wk, ovaries from In{alpha} 215–234-immunized mice consistently appeared atrophic with few viable follicles (lower left). In contrast, ovaries from control mice immunized with CFA alone showed no substantial morphologic changes over the time course of the study and had a similar appearance at both 7–9 wk (upper right) and 43–45 wk (lower right). Solid bar, 200 µm for all sections.

 
Passive transfer of EAO with B cells or sera from In{alpha} 215–234-primed mice

We next determined whether EAO could be transferred into naive recipients either with activated whole splenocytes, activated CD4+ T cells, nonactivated B cells, or sera. SWXJ female mice were immunized with either 200 µg of In{alpha} 215–234 in CFA or with 200 µg of OVA as an irrelevant control Ag. Four weeks after immunization, splenocytes were activated for 4 days with 20 µg/ml priming Ag and 2–4 x 107 cells were injected into naive nonirradiated SWXJ recipients. In some experiments, CD4+ T cells were positively selected from Ag-activated cultures by magnetic bead separation, and the purified (>90–95%) CD4+ T cells were injected at 2–4 x 107 cells into naive SWXJ recipients. Similarly, 4 wk after immunization, B cells were purified (>90%) directly from spleens of primed mice without any prior in vitro activation using B220 microbead cell separation on a Midi MACS column (Miltenyi Biotec). The purified B cells were injected at 2–4 x 107 cells/naive recipient. Finally, 4 wk after immunization, sera from mice immunized with either In{alpha} 215–234 or OVA were injected into naive recipient mice who received a total of four injections of 300 µl of sera administered every other day. Four weeks after transfer of cells or sera, female mice from test and control groups were mated with the same male mice for determining the impact of immunization on fertility and litter size.

We found significantly increased litter sizes in mice that received peptide-activated splenocytes (p = 0.003), nonactivated B cells (p = 0.003), or sera (p = 0.0009) from In{alpha} 215–234-immunized mice, but did not occur in mice that received Ag-activated CD4+ T cells (p = 0.37; Fig. 4A) from peptide-immunized mice. Our data fulfill Koch’s postulate by showing a classic pattern of humoral-mediated disease thereby indicating that the EAO enhanced fertility induced by immunization with In{alpha} 215–234 is a CD4-initiated event ultimately mediated by inhibin-{alpha} autoantibodies.


Figure 4
View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 4. Passive transfer of EAO with B cells and serum. A, Four weeks after immunization of SWXJ females with either In{alpha} 215–234 or OVA, Ag-activated splenocytes, Ag-activated CD4+ T cells, nonactivated B cells, or sera were transferred into naive recipients who were then mated for determining the impact of transfer on litter size. Significantly increased litter sizes occurred in mice that received In{alpha} 215–234-activated splenocytes (p = 0.003), nonactivated B cells (p = 0.003), or sera (p = 0.0009), but did not occur in mice that received Ag-activated CD4+ T cells (p = 0.37). Error bars show ± SD. B, Eight weeks after immunization of female SWXJ mice with In{alpha} 215–234, sera showed high In{alpha} 215–234 Ab titers involving all tested isotypes (left panel). CFA-immunized control mice showed no serum reactivity to In{alpha} 215–234 at 8 wk. Titers 1/256 through 1/8192 represent serial 2-fold serum dilutions from the most concentrated (1/256) through the most dilute (1/8192). PBS was substituted for diluted sera in the PBS control. Error bars show ±SD.

 
EAO results in high inhibin-{alpha} Ab titers

We next characterized the inhibin-{alpha} autoantibodies generated during the period of enhanced fertility. Eight weeks after immunization with either In{alpha} 215–234 or CFA, sera were collected at diestrus and serially diluted for determining isotype titers by direct ELISA. High In{alpha} 215–234 Ab titers involving all tested isotypes were evident in In{alpha} 215–234-immunized mice (Fig. 4B, left) but not in CFA control-immunized mice (Fig. 4B, right). Titers were often remarkably high, and in several mice immunoreactivity was clearly detectable at dilutions exceeding 1/64,000. The predominant isotypes responding to In{alpha} 215–234 included IgG2b, an Ab isotype predominantly induced by TGFbeta, and IgG1, a Th2-associated Ab isotype predominantly induced by IL-4 and inhibited by IFN-{gamma}. Surprisingly, the Th1-associated Ab isotypes IgG2a and IgG3 known to be induced by IFN-{gamma} and inhibited by IL-4 were somewhat underrepresented in the response to In{alpha} 215–234. Perhaps, the response to this potent self-immunogen was so robust that it induced a broad spectrum of both Th1- and Th2-associated Ab isotypes. Nevertheless, a systemic autoantibody response to In{alpha} 215–234 involving a broad spectrum of Ab isotypes was readily detectable during the period when mice showed enhanced fertility.

EAO is mediated by Ab neutralization of inhibin-{alpha}

As indicated previously, serum inhibin-{alpha} concentrations were elevated during the entire course of the estrous cycle, yet their increased levels were unable to prevent the activin-induced FSH surge that was evident during estrus and the superovulation and increased litter sizes that define the observed enhanced fertility in mice immunized with In{alpha} 215–234. We hypothesized that this apparent paradoxical finding may be due to Ab-mediated neutralization of inhibin-{alpha} leading to its failure to down-regulate activin-induced FSH release. Thus, inhibin may be up-regulated and antigenically available for detection but biologically unavailable for antagonizing activin induction of FSH.

To test this hypothesis, we used the LbetaT2 gonadotroph cells which are mouse pituitary cells immortalized by transformation with a rat LHbeta promoter linked to the protein coding sequences of the SV40 T-Ag (Tag) oncogene (40). Inhibin ordinarily inhibits activin-induced secretion of FSH from LbetaT2 cells (41). LbetaT2 cells were stimulated with 25 ng/ml recombinant activin in the presence of sera from mice immunized 8 wk prior with either In{alpha} 215–234 or CFA. Increasing doses of recombinant inhibin were added to these cultures to determine the dose at which inhibin inhibited activin-induced FSH release from the LbetaT2 cells. In cultures containing control sera from CFA-primed mice, increasing doses of inhibin were able to inhibit activin-induced FSH release from LbetaT2 cells, and complete inhibition of activin-induced FSH production was clearly evident when inhibin concentrations reached 20 ng/ml (Fig. 5). In contrast, increasing concentrations of inhibin up to 25 ng/ml had virtually no inhibitory effect on activin-induced FSH release in cultures containing sera from In{alpha} 215–234-immunized mice. Thus, sera from In{alpha} 215–234-immunized mice contained high titers of inhibin neutralizing Ab capable of preventing inhibin-mediated down-regulation of activin-induced FSH secretion.


Figure 5
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 5. EAO is caused by Ab-mediated neutralization of inhibin-{alpha}. Transformed LbetaT2 pituitary cells were stimulated with 25 ng/ml recombinant activin in the presence of sera from mice immunized 8 wk prior with either In{alpha} 215–234 or CFA. In cultures containing control sera from CFA-immunized mice, increasing doses of inhibin were able to inhibit activin-induced FSH release from LbetaT2 cells, and complete inhibition of activin-induced FSH production was evident when inhibin concentrations reached 20 ng/ml. In contrast, increasing concentrations of inhibin up to 25 ng/ml had virtually no inhibitory effect on activin-induced FSH release in cultures containing sera from In{alpha} 215–234-immunized mice. Error bars show ± SD.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
We have shown that a targeted CD4+ T cell-initiated attack directed against the pituitary-gonadal regulatory axis results in a biphasic form of EAO characterized by an early stage of enhanced fertility and a later stage of POF. In addition, we found that B cells and Abs specific for the In{alpha} 215–234-priming immunogen are sufficient for transferring the enhanced fertility into naive recipients. The underlying mechanism for the enhanced fertility involves the high serum levels of inhibin-neutralizing Abs that prevent inhibin-mediated down-regulation of activin-induced pituitary FSH production. The loss of activin down-regulation causes increased pituitary production of FSH leading sequentially to prolongation of the metestrus-diestrus stage of the estrous cycle, increased follicle development, superovulation, and ultimately a significant increase in litter size.

The importance of our study lies in the fact that the ultimate infertility outcome mimics human POF because these affected mice show decreased fertility in the presence of elevated FSH levels, the hallmark features of human POF. Other models used for human POF include those that target ZP oocyte Ags resulting in autoimmune destruction of oocytes (8, 9, 11, 12, 13, 14) and those that involve the immune regulatory failure occurring in athymic or neonatally thymectomized mice (15, 16, 17). However, it is currently unclear whether any of these other POF models have documented FSH hormonal dysregulation similar to that occurring in both human POF and in mice immunized to inhibin-{alpha}. Thus, our inhibin-targeted model provides clinically useful insights into how autoimmune events may lead to elevated FSH and POF. Moreover, aromatase- and estrogen-producing granulosa cells surrounding the ZP layer would be likely suspects in targeting such autoreactivity particularly because the primary targets in human POF appear to be the steroid-producing cells rather than cells of the primordial or secondary follicles. Thus, our inhibin-targeted granulosa cell-targeted EAO model serves as a useful mimic of human POF, a disorder that affects an estimated 1% of women in their childbearing years and is a prominent women’s health risk and cause of human infertility (1, 2, 42, 43).

Despite the fact that inhibin-targeted autoimmunity mimics POF, there are surprisingly no definitive studies that have investigated whether inhibin autoantibodies occur in POF. It is widely believed that enzymes involved in steroid production may be likely Ab targets in POF, particularly in cases associated with Addison’s disease. Such autoantibodies have been characterized as steroid cell Abs including Abs to P450-17{alpha}-hydroxylase and its side chain cleavage product (7, 44). Abs to FSH and LH hormones and to FSH and LH receptors have been reported in POF but only in a small number of patients (45, 46, 47, 48). Similarly, autoantibodies specific for ZP proteins occur in <2.5% of POF patients (49). Therefore, it would seem reasonable to determine whether inhibin autoantibodies occur in POF sera. These experiments are currently under way in our laboratory.

Mediation of human POF by inhibin autoantibodies has some substantial clinical implications not the least of which is the fact that it implies that the period of infertility is preceded by a period of enhanced fertility. It is possible that this stage of increased fertility may not be detected particularly if the affected women are attempting to have children. Thus, a woman in her 20s may undergo a clinically silent period of superovulation and enhanced fertility that remains undetectable. Upon reaching her 30s, the woman may repeatedly fail to bear children at which time she seeks medical intervention and discovers that her infertility is associated with altered pituitary-ovarian regulation and high serum FSH levels. Given this scenario, human POF may possibly be biphasic with an early clinically silent and undetected period of enhanced fertility followed by a detected later period of infertility with accompanying elevated serum FSH levels. The early period of enhanced fertility would likely be detected only if the woman became pregnant and had multiple births. This scenario provides a most interesting perspective that spontaneous multiple births may in some cases be autoimmune-mediated events.

Another clinical implication of our findings lies in the potential of inhibin Abs to mediate superovulation, the major objective of in vitro fertilization (IVF) programs. Currently, IVF programs achieve superovulation by administering an expensive array of menotropin and gonadotropin hormone treatments over an extended period of time. The hormone treatment approach is effective in stimulating ovaries, yet it is quite costly and it is associated with some health risks, most notably ovarian hyperstimulation syndrome (50). It may be possible to replace the hormone-mediated superovulation approach with an Ab approach particularly one with an inherent or bioengineered short half-life.

Finally, an important question remaining to be addressed is the issue of whether both phases of EAO are mediated by transfer of B cells and/or sera and whether In{alpha} 215–234-specific CD4+ T cells play a role in mediating or accelerating the later stage of POF onset. It is quite possible that the eventual development of POF may be due simply to depletion of primordial follicles secondary to chronic FSH-mediated superovulation. Alternatively, the observed POF may be accelerated by T cell-mediated destruction of granulosa cells and subsequent failure to develop any remaining primordial follicles. In the former case, the anticipated appearance of POF would depend exclusively on the transfer of primed B cells and/or sera, whereas in the latter case, the development of POF would be accelerated in the presence of inhibin-activated CD4+ T cells. Experiments designed to address this issue are currently underway.

In summary, we have found that autoimmune-mediated disruption of the pituitary-gonadal regulatory axis causes a form of murine POF that closely mimics human POF. This finding has substantial implications for understanding human POF and for developing effective alternative therapies for the treatment of autoimmune-mediated infertility.


   Acknowledgments
 
We thank Dr. Pamela L. Mellon of the University of California, San Diego for generously providing us with the immortalized LbetaT2 gonadotroph cell line. We also thank Linda Vargo for her excellent histologic support.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Grants AI-51837, (to V.K.T.). Back

2 Address correspondence and reprint requests to Dr. Vincent K. Tuohy, Department of Immunology, Lerner Research Institute, Cleveland Clinic, NB30, 9500 Euclid Avenue, Cleveland, OH 44195. E-mail address: tuohyv{at}ccf.org Back

3 Abbreviations used in this paper: POF, premature ovarian failure; FSH, follicle-stimulating hormone; EAO, experimental autoimmune oophoritis; ZP, zona pellucida; LH, luteinizing hormone; LNC, lymph node cell; IVF, in vitro fertilization. Back

Received for publication March 14, 2006. Accepted for publication May 5, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Coulam, C. B., S. C. Adamson, J. F. Annegers. 1986. Incidence of premature ovarian failure. Obstet. Gynecol. 67: 604-606. [Medline]
  2. Anasti, J. N.. 1998. Premature ovarian failure: an update. Fertil. Steril. 70: 1-15. [Medline]
  3. Marzotti, S., A. Falorni. 2004. Addison’s disease. Autoimmunity 37: 333-336. [Medline]
  4. Hoek, A., Y. van Kasteren, M. de Haan-Meulman, H. Hooijkaas, J. Schoemaker, H. A. Drexhage. 1995. Analysis of peripheral blood lymphocyte subsets, NK cells, and delayed type hypersensitivity skin test in patients with premature ovarian failure. Am. J. Reprod. Immunol. 33: 495-502.
  5. Chernyshov, V. P., T. V. Radysh, I. V. Gura, T. P. Tatarchuk, Z. B. Khominskaya. 2001. Immune disorders in women with premature ovarian failure in initial period. Am. J. Reprod. Immunol. 46: 220-225.
  6. Luborsky, J., B. Llanes, S. Davies, Z. Binor, E. Radwanska, R. Pong. 1999. Ovarian autoimmunity: greater frequency of autoantibodies in premature menopause and unexplained infertility than in the general population. Clin. Immunol. 90: 368-374. [Medline]
  7. Forges, T., P. Monnier-Barbarino, G. C. Faure, M. C. Bene. 2004. Autoimmunity and antigenic targets in ovarian pathology. Hum. Reprod. Update 10: 163-175. [Abstract/Free Full Text]
  8. Jankovic, B. D., B. M. Markovic, S. Petrovic, K. Isakovic. 1973. Experimental autoimmuno-oophoritis in the rat. Eur. J. Immunol. 3: 375-377. [Medline]
  9. Ivanova, M., V. Bourneva, L. Gitsov, Z. Angelova. 1984. Experimental immune oophoritis as a model for studying the thymus-ovary interaction. I. Morphological studies. Am. J. Reprod. Immunol. 6: 99-106. [Medline]
  10. Damjanovic, M.. 1991. Experimental autoimmune oophoritis. II. Both Iymphoid cells and antibodies are successful in adoptive transfer. Autoimmunity 9: 217-223. [Medline]
  11. Wood, D. M., C. Liu, B. S. Dunbar. 1981. The effect of alloimmunization and heteroimmunization with zonae pellucidae on fertility in rabbits. Biol. Reprod. 25: 439-450. [Abstract]
  12. Lou, Y., K. S. Tung. 1993. T cell peptide of a self-protein elicits autoantibody to the protein antigen: implications for specificity and pathogenetic role of antibody in autoimmunity. J. Immunol. 151: 5790-5799. [Abstract]
  13. Dean, J.. 1992. Biology of mammalian fertilization: role of the zona pellucida. J. Clin. Invest. 89: 1055-1059. [Medline]
  14. Hoek, A., J. Schoemaker, H. A. Drexhage. 1997. Premature ovarian failure and ovarian autoimmunity. Endocr. Rev. 18: 107-134. [Abstract/Free Full Text]
  15. Taguchi, O., Y. Nishizuka, T. Sakakura, A. Kojima. 1980. Autoimmune oophoritis in thymectomized mice: detection of circulating antibodies against oocytes. Clin. Exp. Immunol. 40: 540-553. [Medline]
  16. Tung, K. S., S. Smith, C. Teuscher, C. Cook, R. E. Anderson. 1987. Murine autoimmune oophoritis, epididymoorchitis, and gastritis induced by day 3 thymectomy: immunopathology. Am. J. Pathol. 126: 293-302. [Abstract]
  17. Smith, H., Y. H. Lou, P. Lacy, K. S. Tung. 1992. Tolerance mechanism in experimental ovarian and gastric autoimmune diseases. J. Immunol. 149: 2212-2218. [Abstract]
  18. Shelling, A. N., K. A. Burton, A. L. Chand, C. C. van Ee, J. T. France, C. M. Farquhar, S. R. Milsom, D. R. Love, K. Gersak, K. Aittomaki, I. M. Winship. 2000. Inhibin: a candidate gene for premature ovarian failure. Hum. Reprod. 15: 2644-2649. [Abstract/Free Full Text]
  19. Harris, S. E., A. L. Chand, I. M. Winship, K. Gersak, Y. Nishi, T. Yanase, H. Nawata, A. N. Shelling. 2005. INHA promoter polymorphisms are associated with premature ovarian failure. Mol. Hum. Reprod. 11: 779-784. [Abstract/Free Full Text]
  20. Mayo, K. E.. 1994. Inhibin and activin: molecular aspects of regulation and function. Trends Endocrin. Met. 5: 407-415. [Medline]
  21. Groome, N. P., P. J. Illingworth, M. O’Brien, I. Cooke, T. S. Ganesan, D. T. Baird, A. S. McNeilly. 1994. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin. Endocrinol. 40: 717-723. [Medline]
  22. Halvorson, L. M., A. H. DeCherney. 1996. Inhibin, activin, and follistatin in reproductive medicine. Fertil. Steril. 65: 459-469. [Medline]
  23. Kumar, T. R., Y. Wang, N. Lu, M. M. Matzuk. 1997. Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility. Nat. Genet. 15: 201-204. [Medline]
  24. Xu, J., K. McKeehan, K. Matsuzaki, W. L. McKeehan. 1995. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J. Biol. Chem. 270: 6308-6313. [Abstract/Free Full Text]
  25. Dyson, S., J. B. Gurdon. 1998. The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors. Cell. 93: 557-568. [Medline]
  26. Gray, P. C., J. Greenwald, A. L. Blount, K. S. Kunitake, C. J. Donaldson, S. Choe, W. Vale. 2000. Identification of a binding site on the type II activin receptor for activin and inhibin. J. Biol. Chem. 275: 3206-3212. [Abstract/Free Full Text]
  27. Tone, S., Y. Katoh, H. Fujimoto, S. Togashi, M. Yanazawa, Y. Kato, T. Higashinakagawa. 1990. Expression of inhibin {alpha}-subunit gene during mouse gametogenesis. Differentiation 44: 62-68. [Medline]
  28. Albano, R. M., N. Groome, J. C. Smith. 1993. Activins are expressed in preimplantation mouse embryos and in ES and EC cells and are regulated on their differentiation. Development 117: 711-723. [Abstract]
  29. Solares, C. A., A. E. Edling, J. M. Johnson, M.-J. Baek, K. Hirose, G. B. Hughes, V. K. Tuohy. 2004. Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides. J. Clin. Invest. 113: 1210-1217. [Medline]
  30. Kananen, K., M. Markkula, M. Mikola, E. M. Rainio, A. McNeilly, I. Huhtaniemi. 1996. Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin {alpha}-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin {alpha}-subunit gene. Mol. Endocrinol. 10: 1667-1677. [Abstract/Free Full Text]
  31. Pierson, T. M., Y. Wang, F. J. DeMayo, M. M. Matzuk, S. Y. Tsai, B. W. O’Malley. 2000. Regulable expression of inhibin A in wild-type and inhibin {alpha} null mice. Mol. Endocrinol. 14: 1075-1085. [Abstract/Free Full Text]
  32. Durlinger, A. L. L., M. J. G. Gruijters, B. Karels, T. R. Kumar, M. M. Matzuk, U. M. Rose, F. H. de Jong, J. T. Uilenbroek, J. A. Grootegoed, A. P. N. Themmen. 2001. Anti-mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142: 4891-4899. [Abstract/Free Full Text]
  33. Newton, H., Y. Wang, N. P. Groome, P. Illingworth. 2002. Inhibin and activin secretion during murine preantral follicle culture and following HCG stimulation. Hum. Reprod. 17: 38-43. [Abstract/Free Full Text]
  34. National Hormone and Peptide Program (NHPP). 2004. New recombinant hormones, hypothalamic peptides, natural hormones, new antisera, and expanded hormone assay services available. J. Clin. Endocrinol. Metab. 89: 3618-3620. [Free Full Text]
  35. Pedersen, T., H. Peters. 1968. Proposal for a classification of oocytes and follicles in the mouse ovary. J. Reprod. Fertil. 17: 555-557. [Abstract/Free Full Text]
  36. Byskov, A. G. S.. 1974. Cell kinetic studies of follicular atresia in the mouse ovary. J. Reprod. Fertil. 37: 277-285. [Abstract/Free Full Text]
  37. Rugh, R.. 1990. Reproductive systems of adult mice. R. Rugh, ed. The Mouse, Its Reproduction and Development 24-43. Oxford University Press, Oxford.
  38. Miyazaki, S., K. Tanebe, M. Sakai, T. Michimata, H. Tsuda, M. Fujimura, M. Nakamura, Y. Kiso, S. Saito. 2002. Interleukin 2 receptor {gamma} chain ({gamma}c) knockout mice show less regularity in estrous cycle but achieve normal pregnancy without fetal compromise. Am. J. Reprod. Immunol. 47: 222-230.
  39. Pernasetti, F., V. V. Vasilyev, S. B. Rosenberg, J. S. Bailey, H. J. Huang, W. L. Miller, P. L. Mellon. 2001. Cell-specific transcriptional regulation of follicle-stimulating hormone-beta by activin and gonadotropin-releasing hormone in the LbetaT2 pituitary gonadotroph cell model. Endocrinology 142: 2284-2295. [Abstract/Free Full Text]
  40. Turgeon, J. L., Y. Kimura, D. W. Waring, P. L. Mellon. 1996. Steroid and pulsatile gonadotropin-releasing hormone (GnRH) regulation of luteinizing hormone and GnRH receptor in a novel gonadotrope cell line. Mol. Endocrinol. 10: 439-450. [Abstract/Free Full Text]
  41. Graham, K. E., K. D. Nusser, M. J. Low. 1999. LbetaT2 gonadotroph cells secrete follicle stimulating hormone (FSH) in response to active A. J. Endocrinol. 162: R1-5. [Abstract]
  42. Anonymous, M. J.. 1992. Recent advances in medically assisted conception: report of a WHO Scientific Group. World Health Organ. Tech. Rep. Ser. 820: 1-111. [Medline]
  43. Collins, J. A.. 1995. Unexplained infertility. W. R. Keye, Jr, and R. J. Chang, Jr, and R. W. Rebar, Jr, and M. R. Soules, Jr, eds. Infertility: Evaluation and Treatment 249-262. Saunders, Philadelphia.
  44. Falorni, A., S. Laureti, P. Candeloro, S. Perrino, C. Coronella, A. Bizzarro, A. Bellastella, F. Santeusanio, A. De Bellis. 2002. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil. Steril. 78: 270-279. [Medline]
  45. Chiauzzi, V., S. Cigorraga, M. E. Escobar, M. A. Rivarola, E. H. Charreau. 1982. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins. J. Clin. Endocrinol. Metab. 54: 1221-1228. [Abstract/Free Full Text]
  46. Tang, V. W., C. Faiman. 1983. Premature ovarian failure: a search for circulating factors against gonadotropin receptors. Am. J. Obstet. Gynecol. 146: 816-821. [Medline]
  47. Moncayo, H., R. Moncayo, R. Benz, A. Wolf, C. Lauritzen. 1989. Ovarian failure and autoimmunity: detection of autoantibodies directed against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor complex of bovine corpus luteum. J. Clin. Invest. 84: 1857-1865. [Medline]
  48. Luborsky, J. L., L. Visintin, S. Boyers, T. Asari, B. Caldwell, A. DeCherney. 1990. Ovarian antibodies detected by immobilized antigen immunoassay in patients with premature ovarian failure. J. Clin. Endocr. Metab. 70: 69-75. [Abstract/Free Full Text]
  49. Kamada, M., T. Daitoh, K. Mori, N. Maeda, K. Hirano, M. Irahara, T. Aono, T. Mori. 1992. Etiological implication of autoantibodies to zona pellucida in human female infertility. Am. J. Reprod. Immunol. 28: 104-109.
  50. Avecillas, J. F., T. Falcone, A. C. Arroliga. 2004. Ovarian hyperstimulation syndrome. Crit. Care Clin. 20: 679-695. [Medline]

Related articles in The JI:

IN THIS ISSUE

The JI 2006 177: 1373-1374. [Full Text]  



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. Tsigkou, S. Marzotti, L. Borges, A. Brozzetti, F. Reis, P. Candeloro, M. Luisa Bacosi, V. Bini, F. Petraglia, and A. Falorni
High Serum Inhibin Concentration Discriminates Autoimmune Oophoritis from Other Forms of Primary Ovarian Insufficiency
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1263 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. L. Chand, G. T. Ooi, C. A. Harrison, A. N. Shelling, and D. M. Robertson
Functional analysis of the human inhibin {alpha} subunit variant A257T and its potential role in premature ovarian failure
Hum. Reprod., December 1, 2007; 22(12): 3241 - 3248.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Altuntas, C. Z.
Right arrow Articles by Tuohy, V. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Altuntas, C. Z.
Right arrow Articles by Tuohy, V. K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS